Aug. 19, 2025 — Idorsia Ltd recently announced its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the management of systemic hypertension, published by the American College of Cardiology (ACC) and the American Heart Association (AHA) Joint Committee. The updated recommendations now list Tryvio as a therapy that may be added for adults with difficult-to-control hypertension, including resistant hypertension. Tryvio is the first systemic hypertension treatment to target a new pathway in over 30 years and the only new medicine to be included in the updated guidelines.
Despite progress in improving patient outcomes, hypertension remains a major global health issue, and the number one modifiable risk factor of early morbidity/mortality, affecting an estimated 50% of adults in the US, with 50% of those patients not well controlled despite being on medication.
Tryvio is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. The recommended dosage of Tryvio is 12.5 mg orally once daily, with or without food. Tryvio is ideally positioned to treat patients with hypertension and chronic kidney disease (CKD), as the label indicates use in patients with eGFR as low as 15 mL/min. Tryvio’s blood pressure lowering effect was also consistent among subgroups defined by age, sex, race, BMI, baseline UACR, and medical history of diabetes.
Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented, “Idorsia is grateful to the medical community and the joint guidelines committee for recognizing Tryvio as an important option for patients with difficult-to-control hypertension. The clinical evidence from the development program has demonstrated that targeting the endothelin pathway in hypertension with Tryvio can help address a critical unmet medical need. The Tryvio approval and inclusion in the updated clinical practice guidelines are a testament to our commitment to discover and develop innovative medicines that improve patient outcomes.”
The new guidelines will be discussed at the upcoming American Heart Association's (AHA) Hypertension Scientific Sessions held September 4-7, 2025, in Baltimore, MD.
For more information, go to www.idorsia.com,
September 09, 2025 
